Japan has listed 14 drugs not yet launched in the country as “urgently needed,” of which nine have not yet entered local development, despite the high medical demand. The list includes artesunate for severe malaria and several products for treatment-resistant infections, including Viatris’s pretomanid and Paratek Pharma’s Nuzyra (omadacycline).
The Ministry of Health, Labour and Welfare (MHLW) said it will hold further discussions on whether it should request any domestic firms to push
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?